Welcome to our dedicated page for PMGC Holdings news (Ticker: elab), a resource for investors and traders seeking the latest updates and insights on PMGC Holdings stock.
PMGC Holdings Inc. (NASDAQ: ELAB) delivers innovative solutions across biopharmaceuticals, medical aesthetics, and strategic investments. This news hub provides investors with centralized access to all corporate announcements, regulatory updates, and market developments.
Track timely updates on clinical trial progress, partnership agreements, and financial performance. Find press releases covering engineered probiotic therapies for metabolic health, advancements in aesthetic medicine technologies, and strategic moves in fire prevention and energy sectors.
Our curated news collection enables informed decision-making through verified updates on FDA milestones, acquisition activity, and leadership changes. Bookmark this page for ongoing insights into ELAB's diversified growth strategy across healthcare and essential infrastructure markets.
Northstrive Biosciences, a subsidiary of PMGC Holdings (NASDAQ: ELAB), has filed four new patent applications for its drug candidates EL-22 and EL-32. The patents cover two key areas: animal market applications and muscle loss treatment in obese patients, particularly in combination with GLP-1 receptor agonists.
The patent applications include:
- EL-22 for muscle growth in animals
- EL-32 as a standalone therapy for obesity-related muscle loss
- EL-32 in combination with GLP-1 drugs
- EL-32 as an animal feed additive
These additions bring Northstrive's intellectual property portfolio to 8 patent applications and 5 issued patents, with protection across major markets including the USA, Japan, China, and Korea. The company's engineered probiotic platform aims to preserve muscle mass while reducing fat mass in obesity treatment, with potential expansion into animal health markets.
Northstrive Biosciences, a subsidiary of PMGC Holdings (NASDAQ: ELAB), announced that Co-Founder Deniel Mero was featured in a Bear Bull Traders interview discussing recent FDA preliminary meeting responses. The responses support their plans for EL-22, a myostatin-engineered probiotic treatment designed to preserve muscle during weight loss with GLP-1 receptor agonists.
The FDA's feedback supports moving forward with an Investigational New Drug (IND) application for a Phase 2 clinical trial targeting overweight or obese patients. Bear Bull Traders, founded by Andrew Aziz, reaches 595,000 YouTube subscribers and maintains a network of over 7,000 active members and 100,000 newsletter subscribers globally.
Northstrive Biosciences, a subsidiary of PMGC Holdings (NASDAQ: ELAB), received positive FDA preliminary responses regarding their pre-IND meeting for EL-22, a novel engineered probiotic designed for obesity treatment in combination with GLP-1 receptor agonists.
The FDA's feedback supported that:
- Pharmacology studies demonstrate EL-22 activity
- Nonclinical studies adequately support safety and activity in overweight/obese populations
- Phase 1 study data and nonclinical studies appear sufficient for initiating Phase 2 trials
EL-22 targets the myostatin pathway to support muscle health during weight loss treatments. The company plans to file an IND application in 2025 to initiate Phase 2 clinical trials. Previous Phase 1 trials in South Korea showed the treatment was generally well-tolerated and safe in healthy volunteers.
PMGC Holdings Inc. (NASDAQ: PMGC) has announced signing a non-binding Letter of Intent (LOI) to acquire a U.S.-based custom IT packaging company. The acquisition target brings significant operational experience with nearly 15 years of history and serves over 300 commercial clients including data centers, technology manufacturers, and IT service providers.
The target company demonstrates strong market presence with 90% U.S.-based revenue and maintains recurring business relationships. The company is notably cash-flow positive, indicating established operational stability.
Northstrive Biosciences, a subsidiary of PMGC Holdings (NASDAQ: ELAB), has entered into a Development and License Agreement with Yuva Biosciences to develop AI-powered therapies for obesity and cardiometabolic diseases. The collaboration will utilize YuvaBio's proprietary MitoNova™ platform to discover novel pharmaceutical treatments.
The partnership focuses on developing compounds that promote mitochondrial health and target cellular aging. YuvaBio will provide Northstrive with exclusive worldwide licensing rights for therapeutic products in cardiac diseases and obesity. The multi-phase collaboration includes in silico modeling, virtual compound screening, and experimental testing.
The agreement includes: (1) an upfront fee and phase-completion payments, (2) developmental milestone payments, and (3) royalties on net sales of therapeutic products containing compounds identified through the program.
PMGC Holdings Inc. (NASDAQ: ELAB) has announced the filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, with the Securities and Exchange Commission (SEC). The report is accessible on both the SEC's website and the company's investor relations platform.
The company states it is actively pursuing acquisition opportunities of operating businesses and assets as part of its strategic growth initiatives, aiming to drive revenue growth and enhance shareholder value.
PMGC Holdings (NASDAQ: ELAB) subsidiary NorthStrive Biosciences has announced a significant amendment to its existing licensing agreement with MOA Life Plus Co., The amendment expands NorthStrive's license rights for EL-32 and EL-22 to include all applications in animal health and feed additives.
The strategic move positions NorthStrive to tap into the U.S. animal health market, valued at $12.65 billion in 2024 with an expected CAGR of 7.97% from 2025 to 2030. The market growth is driven by innovations in companion animal pharmaceuticals, increasing millennial pet adoption rates, growing livestock populations, and rising meat/milk consumption rates.
PMGC Holdings Inc. (Nasdaq: ELAB) has announced a registered direct offering priced at-the-market under Nasdaq rules, aiming to raise approximately $1.48 million. The company has entered into definitive agreements with investors for the sale of 294,450 shares of common stock at $5.04 per share.
The offering includes pre-funded warrants with an exercise price of $0.001 per share. Following the offering, PMGC will have approximately 872,411 shares of common stock outstanding. The transaction is expected to close around March 24, 2025, subject to customary closing conditions.
Univest Securities, is serving as the sole placement agent for the offering, which is being conducted under a shelf registration statement on Form S-3 previously declared effective by the SEC on February 7, 2025.
PMGC Holdings (NASDAQ: ELAB) has announced the repurchase of shares from select existing shareholders who directly approached the company. The transactions' details are documented in Form 8-K filings available on sec.gov.
The company states it will evaluate additional share repurchase opportunities from other investors, subject to market conditions. Interested shareholders are instructed to submit written requests to PMGC's Newport Beach headquarters.
PMGC emphasizes this is not a formal share repurchase program or tender offer, and future repurchases remain at the company's discretion in response to unsolicited shareholder inquiries.
Northstrive Biosciences, a subsidiary of PMGC Holdings (NASDAQ: ELAB), has scheduled a pre-IND meeting with the FDA for April 23, 2025 to discuss their novel obesity treatment EL-22. The therapy combines an engineered probiotic approach with GLP-1 receptor agonists, specifically targeting muscle preservation during weight loss.
EL-22 is designed to express myostatin on its surface, aiming to support muscle health through the myostatin pathway. The treatment has shown promising results in preclinical studies, including significant improvements in mdx mice studies published in 2022. Additionally, EL-22 has completed a Phase 1 clinical trial in South Korea, demonstrating general tolerability and safety in healthy volunteers.
Following FDA feedback, Northstrive plans to file an Investigational New Drug application in 2025 and begin clinical trials evaluating EL-22's combination with GLP-1 receptor agonists for obesity treatment.
FAQ
What is the current stock price of PMGC Holdings (elab)?
What is the market cap of PMGC Holdings (elab)?
